Banque Pictet & Cie SA Sells 118,540 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Banque Pictet & Cie SA lessened its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 62.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 70,693 shares of the medical research company's stock after selling 118,540 shares during the quarter. Banque Pictet & Cie SA's holdings in Exact Sciences were worth $3,972,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Huntington National Bank raised its stake in Exact Sciences by 838.1% during the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company's stock worth $27,000 after buying an additional 352 shares during the period. RPg Family Wealth Advisory LLC acquired a new stake in Exact Sciences during the 3rd quarter worth $34,000. Capital Performance Advisors LLP acquired a new stake in Exact Sciences during the 3rd quarter worth $35,000. Modus Advisors LLC acquired a new stake in shares of Exact Sciences in the 4th quarter valued at about $43,000. Finally, Vestor Capital LLC acquired a new stake in shares of Exact Sciences in the 3rd quarter valued at about $46,000. Institutional investors and hedge funds own 88.82% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Sanford C. Bernstein lifted their price target on Exact Sciences from $75.00 to $90.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. Stifel Nicolaus dropped their price target on Exact Sciences from $82.00 to $67.00 and set a "buy" rating on the stock in a research note on Wednesday, November 6th. Citigroup dropped their price target on Exact Sciences from $80.00 to $75.00 and set a "buy" rating on the stock in a research note on Wednesday, November 6th. Robert W. Baird dropped their price target on Exact Sciences from $70.00 to $67.00 and set an "outperform" rating on the stock in a research note on Wednesday, November 6th. Finally, TD Cowen lifted their target price on Exact Sciences from $82.00 to $86.00 and gave the company a "buy" rating in a research report on Tuesday, November 26th. One analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat.com, Exact Sciences presently has an average rating of "Moderate Buy" and an average price target of $72.76.

Exact Sciences Stock Performance

Shares of NASDAQ:EXAS traded up $0.32 during trading on Tuesday, reaching $49.63. 2,971,788 shares of the stock were exchanged, compared to its average volume of 2,145,480. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $79.62. The firm has a market cap of $9.19 billion, a PE ratio of -42.42 and a beta of 1.24. The stock has a 50-day moving average price of $55.90 and a 200-day moving average price of $60.23. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.